Please login to the form below
MabThera
This page shows the latest MabThera news and features for those working in and with pharma, biotech and healthcare.
Celgene’s Revlimid scores NICE approval in follicular lymphoma
Revlimid (lenalidomide) has been recommended for use with Roche’s MabThera (rituximab) – also known as R2 regimen – for the treatment of adult patients with previously-treated grade 1 to 3A follicular ... Revlimid plus MabThera demonstrated a
Latest news
-
Roche posts minor sales miss in Q4 as biosimilar pressure grows
All told, the Swiss group’s pharma sales came in at CHF 12bn ($12.35bn), with its ‘big three’ antibodies – Avastin (bevacizumab), Herceptin (trastuzumab) and Rituxan/MabThera (rituximab) – all on the
-
Mylan, Biocon’s Herceptin biosimilar launched in US
Alongside Herceptin, this includes Avastin (bevacizumab) and MabThera (rituximab) which are also under threat from new biosimilar launches.
-
ChemoCentryx surges on phase 3 vasculitis study
At the moment ANCA vasculitis is treated with a combination of potent steroids like prednisolone with immunosuppressive drugs like cyclophosphamide or Roche’s Rituxan/MabThera (rituximab).
-
Roche wins FDA breakthrough for Gazyva in lupus nephritis
Roche has been counting on a new class of medicines to help offset the biosimilar onslaught on its ageing cancer blockbusters, including Herceptin and MabThera/Rituxan.
-
New products help lift Roche outlook despite biosimilar onslaught
This was all achieved despite heavy erosion of sales in Europe thanks to biosimilars - the group's total sales fell 4% in the region, with Herceptin revenues down 45% and
More from news
Approximately 17 fully matching, plus 110 partially matching documents found.
Latest Intelligence
-
The good, the bad and the ugly
Humira remains at the top, but Celgene’s Revlimid has jumped ahead of Roche’s Avastin, MabThera and Herceptin.
-
Deal Watch November 2016
We are starting to see more deals covering biosimilars and this month Poland-based Mabion signed a supply and commercialisation agreement with Mylan for a biosimilar of Roche's ... competitors. The patents covering MabThera/Rituxan expired in Europe in
-
Pharma deals in June 2015
Roche has two products approved in Europe, Herceptin SC and MabThera SC, and Baxter has HyQvia approved in the US and EU, which utilise the Halozyme approach. ... Herceptin SC and MabThera SC can be administered in approximately 5 minutes by sc injection
-
Russian innovation at the crossroads
For example, in autumn 2014, BIOCAD fully pushed out Roche's Mabthera (rituximab) from public procurement.
-
Pharma deals during December 2014
Subcutaneous formulations of both MabThera and Herceptin based on the Halozyme technology have been launched by Roche.
More from intelligence
Approximately 0 fully matching, plus 9 partially matching documents found.
Latest appointments
-
Sanofi hires David Loew from Roche
He gradually rose up the ranks at Roche, holding senior marketing positions such as life cycle leader for both MabThera and Xeloda, head of oncology and chief marketing officer, before taking
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Latest from PMHub
-
The Biosimilar Challenge
Herceptin, Avastin, Rituximab and Erbitux) and autoimmune disease (e.g. Humira, Enbrel, Remicade, MabThera and RoActemra to name a few).
-
Biosimilars: Getting the flock to market
The greatest attraction, naturally, is high-revenue anti-TNF agents like MabThera (rituximab) and Humira (adalimumab), for many years the world's most valuable drug.
More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
-
Principal Medical Writer
-
Varies on experience
-
Account Management
-
Competitive Salary Offered
- Senior Leadership Role – Medical Communications – North West
-
Highly Competitive Salary, Bonus &Benefits
- Freelance Medical Writer - Creative Healthcare Comms - 2 month t...
-
Excellent Day Rate
- FREELANCE Medical Writer, Senior Medical Writer, Principal Medic...
-
Highly Competitive Day Rate, Bonus &Benefits
- Senior Account / Programme Manager - MedComms - Buckinghamshire
-
Highly Competitive Remuneration packages
- Freelance Account Manager - Creative Healthcare Comms - Immediat...
-
Excellent Day Rate
- Senior Content Editor - Biotechnology
-
Salary TBC
- Pfizer helps fund biotech venture from former researchers at closed Kent facility
- Oxford University to investigate nasal spray delivery of AZ-partnered COVID-19 vaccine
- First dose of Pfizer/BioNTech vaccine reduces COVID-19 infection risk by 70%
- J&J looks ahead at potential flu therapy after approval of its COVID-19 vaccine
- New restrictions for AZ/Oxford COVID-19 vaccine despite EMA endorsement
- Moderna launches COVID-19 vaccine booster study to address new variants
- Sanofi pays $160m upfront to acquire Tidal Therapeutics
- Roche, Regeneron’s COVID-19 antibody cocktail cuts infection risk
- AZ showcases data for next-generation PARP inhibitor AZD5305
- Change for good: the virtual congress audience is too big to be ignored
- 3 tips to show patient diversity in your clinical trial materials
- Live Webinar: Nanobiotechnology, Artificial Intelligence, and Virtual Care
PMHub
ROAD
ROAD is a digital PR and communications consultancy specialising in promoting the innovators that shape our future health and wellbeing....
Latest intelligence
- 3 tips to show patient diversity in your clinical trial materials
- Here are some useful tips to help get your hands on authentically diverse stock photos....
- Virtual congresses: video thrilled the cardio tsar
- Chris Ross explores the key learnings from a year of virtual congresses...
- When Will We Be Back To Normal?
- The definitive question of 2021, whether you’re a homeschooling parent, a homebound professional, a wanderer with nowhere to go… or all three at once....
Quick links
Infographics
